2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2014
PGI29 The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation
Cortesi P, Mantovani L, Ciaccio A, Rota M, Cesana G, Strazzabosco M, Belli L. PGI29 The Cost-Effectiveness Of Sofosbuvir And Ribavirin Treatment In Hcv-Infected Patients Listed For Liver Transplantation. Value In Health 2014, 17: a367-a368. PMID: 27200773, DOI: 10.1016/j.jval.2014.08.826.Chapters